肺がん診断・治療の世界市場（2022年～2028年）

世界の肺がん診断・治療の市場規模は、予測期間中にCAGRで11.3%の大幅な成長が予測されています。効果の高い医薬品が利用できることや、新興国での医薬品承認の増加が、市場の成長を後押ししています。

当レポートでは、世界の肺がん診断・治療市場について調査分析し、市場概要、競合情勢、セグメント分析、地域分析などを提供しています。

目次

第1章 レポートサマリー

第2章 市場概要と考察

• 調査範囲
• アナリストの考察と現在の市場動向

第3章 競合情勢

• 主要企業分析

第4章 市場セグメンテーション

• 世界の肺がん診断・治療市場：タイプ別
  • 非小細胞肺がん
  • 小細胞肺がん
• 世界の肺がん診断・治療市場：治療別
  • クロマトグラフィー
  • 標的療法
  • 免疫療法
  • 放射線治療
  • その他（手術）
• 世界の肺がん診断・治療市場：診断別
  • CTスキャン
  • X線
  • 肺がんスクリーニング
  • 針生検
  • その他（気管支鏡検査、喀痰細胞診）

第5章 地域分析

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• その他の地域

第6章 企業プロファイル

• AbbVie Inc.
• AstraZeneca Plc
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co.
• Daiichi Sankyo Co, Ltd.
• Eisai Co., Ltd.
• Eli Lilly and Co.
• GSK plc.
• Merck & Co., Inc.
• Myriad Genetics, Inc.
• Novartis International AG
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Thermo Fisher Scientific, Inc.
• Qiagen GmbH

LIST OF TABLES

• 1. GLOBAL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY TYPE, 2021-2028 ($ MILLION)
• 2. GLOBAL NON-SMALL CELL LUNG CANCER MARKET BY REGION, 2021-2028 ($ MILLION)
• 3. GLOBAL LUNG CANCER DIAGNOSIS AND THERAPEUTICS FOR DRUG TESTING MARKET BY REGION, 2021-2028 ($ MILLION)
• 4. GLOBAL SMALL CELL LUNG CANCER MARKET BY REGION, 2021-2028 ($ MILLION)
• 5. GLOBAL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY TREATMENT, 2021-2028 ($ MILLION)
• 6. GLOBAL CHROMATOGRAPHY FOR LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY REGION, 2021-2028 ($ MILLION)
• 7. GLOBAL TARGETED THERAPY FOR LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY REGION, 2021-2028 ($ MILLION)
• 8. GLOBAL IMMUNOTHERAPY FOR LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY REGION, 2021-2028 ($ MILLION)
• 9. GLOBAL RADIATION THERAPY FOR LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY REGION, 2021-2028 ($ MILLION)
• 10. GLOBAL OTHERS THERAPY LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY REGION, 2021-2028 ($ MILLION)
• 11. GLOBAL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY DIAGNOSIS, 2021-2028 ($ MILLION)
• 12. GLOBAL CT SCAN FOR LUNG CANCER DIAGNOSIS MARKET BY REGION, 2021-2028 ($ MILLION)
• 13. GLOBAL X-RAYS FOR LUNG CANCER DIAGNOSIS MARKET BY REGION, 2021-2028 ($ MILLION)
• 14. GLOBAL LUNG CANCER SCREENING FOR LUNG CANCER DIAGNOSIS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
• 15. GLOBAL NEEDLE BIOPSY FOR LUNG CANCER DIAGNOSIS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
• 16. GLOBAL OTHERS LUNG CANCER DIAGNOSIS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
• 17. NORTH AMERICAN LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
• 18. NORTH AMERICAN LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
• 19. NORTH AMERICAN LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
• 20. NORTH AMERICAN LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
• 21. EUROPEAN LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
• 22. EUROPEAN LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
• 23. EUROPEAN LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
• 24. EUROPEAN LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
• 25. ASIA-PACIFIC LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
• 26. ASIA-PACIFIC LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
• 27. ASIA-PACIFIC LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
• 28. ASIA-PACIFIC LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
• 29. REST OF THE WORLD LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
• 30. REST OF THE WORLD LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
• 31. REST OF THE WORLD LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)

LIST OF FIGURES

• 1. IMPACT OF COVID-19 ON GLOBAL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET, 2021-2028 ($ MILLION)
• 2. IMPACT OF COVID-19 ON GLOBAL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
• 3. RECOVERY OF GLOBAL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET, 2022-2028 (%)
• 4. GLOBAL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY TYPE, 2021 VS 2028 (%)
• 5. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 6. GLOBAL SMALL CELL LUNG LUNG CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 7. GLOBAL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY TREATMENT, 2021 VS 2028 (%)
• 8. GLOBAL CHEMOTHERAPY FOR LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 9. GLOBAL TARGETED THERAPY FOR LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 10. GLOBAL IMMUNOTHERAPY FOR LUNG CANCER DIAGNOSIS AND MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 11. GLOBAL RADIATION THERAPY FOR LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 12. GLOBAL OTHERS THERAPY FOR LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 13. GLOBAL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY DIAGNOSIS, 2021 VS 2028 (%)
• 14. GLOBAL CT SCAN FOR LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 15. GLOBAL X-RAYS FOR LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 16. GLOBAL LUNG CANCER SCREENING FOR LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 17. GLOBAL NEEDLE BIOPSY FOR LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 18. GLOBAL OTHERS FOR LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 19. US LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2021-2028($ MILLION)
• 20. CANADA MARKET LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2021-2028($ MILLION)
• 21. UK LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2021-2028($ MILLION)
• 22. GERMANY LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2021-2028($ MILLION)
• 23. SPAIN LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2021-2028($ MILLION)
• 24. FRANCE LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2021-2028($ MILLION)
• 25. ITALY LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2021-2028($ MILLION)
• 26. REST OF EUROPE LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2021-2028($ MILLION)
• 27. INDIA LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2021-2028($ MILLION)
• 28. CHINA LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2021-2028($ MILLION)
• 29. JAPAN LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2021-2028($ MILLION)
• 30. REST OF ASIA-PACIFIC LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2021-2028($ MILLION)

31. REST OF WORLD LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2021-2028($ MILLION

Global Lung Cancer Diagnosis & Therapeutics Market Size, Share & Trends Analysis Report by Type (Non-Small-Cell Lung Cancer, and Small-Cell-Lung Cancer) by Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, and Others) by Diagnosis (CT scan, X-Rays, Lung Cancer Screening, Needle Biopsy, and Others) Forecast 2022-2028

The global lung cancer diagnosis and therapeutics market is anticipated to grow at a considerable CAGR of 11.3% during the forecast period. Cigarette smoking and polluted air are the principal risk factors responsible for the emergence of lung cancer. The interpretation of lung cancer is confirmed by biopsy which is done by using bronchoscopy or CT guidance. Hence, the treatment procedure is done by chemotherapy, radiotherapy, immunotherapy, and surgery. Moreover, the availability of highly effective medications, and a growing number of drug approval in the emerging economies, boost the market growth. In October 2021, the FDA has approved the immunotherapy drug atezolizumab, as an additional treatment after surgery and chemotherapy for patients with nonsmall cell lung cancer (NSCLC). The approval is based on results from the IMpower010 clinical trial, which includes more than 1,000 patients suffered from NSCLC.

Additionally, the patent expiry on the currently available drugs and the rising cost of developing the drugs is increasing, which forced the drug manufacturers to minimize their investment in R&D, which in turn hamper the market growth.

The global lung cancer diagnosis & therapeutic market is segmented based on type, treatment, and diagnosis. On the basis of type, the market is bifurcated into non-small cell lung cancer, and small-cell lung cancer. Based on treatment the market is segregated into chemotherapy, targeted therapy, immunotherapy, radiation therapy, and others. Similarly, based on diagnosis, the market is categorized into CT-scan, X-rays, lung cancer screening, needle biopsy, and others. Based on diagnosis needle biopsy segment is expected to grow at the fastest rate, owing to a diagnosis of various types of cancer such as prostate, skin, and breast cancer, as it offers clear visibility and positional accuracy. Moreover, the growing need to detect early signs and symptoms of preventable diseases to increase the survival rate of patients is another factor due to which, the demand for needle biopsy is on the rise.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The North American region dominates the global lung cancer diagnosis and therapeutics market, due to the availability of a large number of regulatory approved cancer drugs, along with innovative and safer therapy treatment services offered by market players in the North America region, leading to a rise in the market in coming years.

The major companies serving the global lung cancer diagnosis & therapeutic market are Daiichi Sankyo Co, Ltd., Eisai Co., Ltd., Eli Lilly and Co., GSK plc. Merck & Co., Inc., Myriad Genetics, Inc. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaboration, funding, and new product launches, to stay competitive in the market. For instance, in November 2021, GE Healthcare and Optellum announced that they signed a letter of intent to collaborate to advance the precision diagnosis and treatment of lung cancer. Optellum virtual nodule clinics identify malignancy in lung nodules, which is a key to determining whether the biopsy is necessary or not. It is the only FDA-cleared AI-assisted diagnosis software for early stage lung cancer.

Research Methodology

The market study of the global lung cancer diagnosis & therapeutic market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Lung Cancer Diagnosis & Therapeutic Market Research And Analysis By Type

2. Global Lung Cancer Diagnosis & Therapeutic Market Research And Analysis By Technology

3. Global Lung Cancer Diagnosis & Therapeutic Market Research and Analysis by Diagnosis

The Report Covers

• Comprehensive research methodology of the global lung cancer diagnosis & therapeutic market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the global lung cancer diagnosis & therapeutic market.
• Insights about market determinants that are stimulating the global lung cancer diagnosis & therapeutic market.
• Detailed and extensive market segments with the regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.

Table of Contents

Category- Medical Devices

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Lung Cancer Diagnosis and Therapeutics Market
• Recovery Scenario of Global Lung Cancer Diagnosis and Therapeutics Market
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. BY Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis

4. Market Segmentation

• 4.1. Global Lung Cancer Diagnosis and Therapeutics Market by Type
  • 4.1.1. Non-Small Cell Lung Cancer
  • 4.1.2. Small Cell Lung Cancer
• 4.2. Global Lung Cancer Diagnosis and Therapeutics Market by Treatment
  • 4.2.1. Chromatography
  • 4.2.2. Targeted Therapy
  • 4.2.3. Immunotherapy
  • 4.2.4. Radiation Therapy
  • 4.2.5. Others (Surgery)
• 4.3. Global Lung Cancer Diagnosis and Therapeutics By Diagnosis
  • 4.3.1. CT-Scan
  • 4.3.2. X-Rays
  • 4.3.3. Lung Cancer Screening
  • 4.3.4. Needle Biopsy
  • 4.3.5. Others (Bronchoscopy, Sputum Cytology)

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. AbbVie Inc.
• 6.2. AstraZeneca Plc
• 6.3. Bayer AG
• 6.4. Boehringer Ingelheim International GmbH
• 6.5. Bristol-Myers Squibb Co.
• 6.6. Daiichi Sankyo Co, Ltd.
• 6.7. Eisai Co., Ltd.
• 6.8. Eli Lilly and Co.
• 6.9. GSK plc.
• 6.10. Merck & Co., Inc.,
• 6.11. Myriad Genetics, Inc.
• 6.12. Novartis International AG
• 6.13. Pfizer Inc.
• 6.14. F. Hoffmann-La Roche Ltd.
• 6.15. Sanofi S.A.
• 6.16. Teva Pharmaceutical Industries Ltd.
• 6.17. Thermo Fisher Scientific, Inc.
• 6.18. Qiagen GmbH